- Stocks
- Healthcare
- NASDAQ: SUPN

Price (delayed)

$32.09

Market cap

$1.7B

P/E Ratio

15.21

Dividend/share

N/A

EPS

$2.11

Enterprise value

$1.84B

Supernus Pharmaceuticals's revenue has increased by 38% YoY and by 7% from the previous quarter

The gross profit is up by 28% YoY and by 5% QoQ

The stock's price to earnings (P/E) is 45% more than its last 4 quarters average of 10.5 but 22% less than its 5-year quarterly average of 19.6

The quick ratio has contracted by 30% YoY and by 7% from the previous quarter

The EPS has declined by 12% since the previous quarter and by 4.5% year-on-year

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Website: https://www.supernus.com

What are the main financial stats of SUPN

Market
Valuations
Earnings

Shares outstanding

53.02M

Market cap

$1.7B

Enterprise value

$1.84B

Price to earnings (P/E)

15.21

Price to book (P/B)

2.25

Price to sales (P/S)

3.05

EV/EBIT

10.54

EV/EBITDA

9.31

EV/Sales

3.31

Revenue

$556.35M

EBIT

$174.64M

EBITDA

$197.64M

Free cash flow

$163.26M

Per share
Balance sheet
Liquidity

EPS

$2.11

Free cash flow per share

$3.08

Book value per share

$14.26

Revenue per share

$10.51

TBVPS

$20.23

Total assets

$1.51B

Total liabilities

$753M

Debt

$394.57M

Equity

$754.44M

Working capital

$345.21M

Debt to equity

0.52

Current ratio

2.43

Quick ratio

2.15

Net debt/EBITDA

0.7

Margins
Efficiency
Dividend

EBITDA margin

35.5%

Gross margin

88.6%

Net margin

20%

Operating margin

28.4%

Return on assets

7.4%

Return on equity

15.5%

Return on invested capital

18.7%

Return on capital employed

13.8%

Return on sales

31.4%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Supernus Pharmaceuticals stock price performed over time

Intraday

-1.5%

1 week

2.85%

1 month

4.8%

1 year

34.49%

YTD

27.54%

QTD

22.57%

How have Supernus Pharmaceuticals's revenue and profit performed over time

Revenue

$556.35M

Gross profit

$493.09M

Operating income

$157.9M

Net income

$111.13M

Gross margin

88.6%

Net margin

20%

Supernus Pharmaceuticals's revenue has increased by 38% YoY and by 7% from the previous quarter

The net margin is down by 31% year-on-year and by 18% since the previous quarter

The gross profit is up by 28% YoY and by 5% QoQ

The company's operating margin fell by 25% YoY and by 15% QoQ

What is Supernus Pharmaceuticals's growth rate over time

What is Supernus Pharmaceuticals stock price valuation

P/E

15.21

P/B

2.25

P/S

3.05

EV/EBIT

10.54

EV/EBITDA

9.31

EV/Sales

3.31

The stock's price to earnings (P/E) is 45% more than its last 4 quarters average of 10.5 but 22% less than its 5-year quarterly average of 19.6

The EPS has declined by 12% since the previous quarter and by 4.5% year-on-year

SUPN's price to book (P/B) is 55% less than its 5-year quarterly average of 5.0 but 25% more than its last 4 quarters average of 1.8

Supernus Pharmaceuticals's equity has increased by 23% YoY

The P/S is 40% below the 5-year quarterly average of 5.1 but 17% above the last 4 quarters average of 2.6

Supernus Pharmaceuticals's revenue has increased by 38% YoY and by 7% from the previous quarter

How efficient is Supernus Pharmaceuticals business performance

The return on sales has declined by 28% year-on-year and by 15% since the previous quarter

The return on assets has declined by 28% year-on-year and by 17% since the previous quarter

SUPN's return on invested capital is up by 25% year-on-year but it is down by 4.6% since the previous quarter

The company's return on equity fell by 24% YoY and by 17% QoQ

What is SUPN's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for SUPN.

How did Supernus Pharmaceuticals financials performed over time

Supernus Pharmaceuticals's total assets is 100% higher than its total liabilities

The company's total liabilities rose by 31% YoY

The quick ratio has contracted by 30% YoY and by 7% from the previous quarter

The debt is 48% smaller than the equity

Supernus Pharmaceuticals's equity has increased by 23% YoY

Supernus Pharmaceuticals's debt to equity has decreased by 16% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.